Recurrent	recurrent	O	O
dysosmia	dysosmia	O	S_disease
induced	induced	O	O
by	by	O	O
pyrazinamide	pyrazinamide	O	O
.	.	O	O

Pyrazinamide	pyrazinamide	O	O
can	can	O	O
have	have	O	O
adverse	adverse	O	B_disease
effects	effects	O	I_disease
such	such	O	O
as	as	O	O
hepatic	hepatic	O	O
toxicity	toxicity	O	O
,	,	O	O
hyperuricemia	hyperuricemia	O	S_disease
or	or	O	O
digestive	digestive	O	O
disorders	disorders	O	O
.	.	O	O

In	in	O	O
rare	rare	O	O
cases	cases	O	O
,	,	O	O
alterations	alterations	O	O
in	in	O	O
taste	taste	O	O
and	and	O	O
smell	smell	O	O
function	function	O	O
have	have	O	O
been	been	O	O
reported	reported	O	O
for	for	O	O
pyrazinamide	pyrazinamide	O	O
when	when	O	O
combined	combined	O	O
with	with	O	O
other	other	O	O
drugs	drugs	S_chemicals	O
.	.	O	O

We	we	O	O
report	report	O	O
a	a	O	O
case	case	O	O
of	of	O	O
reversible	reversible	O	O
olfactory	olfactory	O	O
disorder	disorder	O	O
related	related	O	O
to	to	O	O
pyrazinamide	pyrazinamide	O	O
in	in	O	O
a	a	O	O
woman	woman	O	O
,	,	O	O
with	with	O	O
a	a	O	O
positive	positive	O	O
rechallenge	rechallenge	O	O
.	.	O	O

The	the	O	O
patient	patient	O	O
presented	presented	O	O
every	every	O	O
day	day	O	O
a	a	O	O
sensation	sensation	O	O
of	of	O	O
smelling	smelling	O	O
something	something	O	O
burning	burning	O	O
15	15	O	O
min	min	O	O
after	after	O	O
drug	drug	S_chemicals	O
intake	intake	O	O
.	.	O	O

Dysosmia	dysosmia	O	S_disease
disappeared	disappeared	O	O
completely	completely	O	O
after	after	O	O
pyrazinamide	pyrazinamide	O	O
withdrawal	withdrawal	O	O
and	and	O	O
recurred	recurred	O	O
after	after	O	O
its	its	O	O
rechallenge	rechallenge	O	O
.	.	O	O

The	the	O	O
case	case	O	O
was	was	O	O
reported	reported	O	O
to	to	O	O
the	the	O	O
Tunisian	tunisian	O	O
Centre	centre	O	O
of	of	O	O
Pharmacovigilance	pharmacovigilance	O	O
.	.	O	O

